BUSINESS MIX

Today, one of the major epidemics challenging the global community is HIV/AIDS. Inspite of its late entry into India, our country has the largest number of HIV infected population because of the phenomenal spread.

The only ray of hope to HIV infected is HAART (Highly Active Antiretroviral Therapy), a combination of different classes of drugs that can halt the progression of the disease and improve the quality and quantity of life of patients.

In India, HAART was not available until a year ago, and was with limited drug options. The prices of the drugs were exorbitant and the treatment was not affordable to many. Added to the problem is the trauma in the family and apathy of the society towards the HIV infected. The need of the hour is definitely a positive outlook towards the HIV positive.

Imunus, the antiviral division of Aurobindo Pharma, is networking an effort to arrest the progression of HIV to AIDS. The mission at Imunus is to offer wider product options at affordable prices. Imunus also strives to network with government organisations/NGOs to motivate patients to take treatment and mobilize funds for them.

Aurobindo Pharma has significantly brought down the cost of ART in India by over 50% and has introduced over 11 drug options in three different classes of drugs, within a period of 9 months of its introduction. Today, Imunus has a comprehensive coverage of over 3000 doctors, regularly servicing them with scientific information through Continuous Medical Education programmes.

Imunus is working in tandem with NGO/government organisations in developing educational programmes on treatment. Imunus is also servicing various institutions like Andhra Pradesh/Assam/Uttar Pradesh/Madhya Pradesh State AIDS Control Societies through regular antiretroviral supplies.

With a constant endeavor to develop new therapeutic agents, efforts are now in progress to develop speciality generic formulations to reduce pill burden and enhance patient compliance.

At Imunus the belief is "Together we can nurture a positive outlook for the HIV positive".

Imunus Product Portfolio

BRAND DOSAGE
Compliance Tablets
ZIDOVEX-LN (Zidovudine 300mg + Lamivudine 150mg +
Nevirapine 200mg Tabs)
STAVEX - 30 LN (Stavudine 30mg + Lamivudine 150mg + Nevirapine 200mg Tabs) 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
ZIDOVEX (Zidovudine 100mg Caps/300mg Tabs)
LAMIVOX (Lamivudine 150mg Tabs)
STAVEX (Stavudine 30mg/40mg Caps)
ZIDOVEX-L (Zidovudine 300mg + Lamivudine 150mg Tabs) 
STAVEX-30 L (Stavudine 30mg + Lamivudine 150mg + Nevirapine 200mg Tabs)
Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
NEVIREX (Nevirapine 200mg Tabs)
VIRANZ (Efavirenz 200mg Caps)
Protease Inhibitors (PIs)
NELVEX (Nelfinavir 250mg Tabs)
INDIVEX (Indinavir 400mg Caps)

Top

 ____________________________________________________________________